Clinical Trial

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2023 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together. Randomized stage is designed to evaluate the OS and PFS in patients receiving KN026 and chemotherapy compared to patients receiving placebo and chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-06-16.
Trial Details
NCT Number NCT05427383
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Stomach Cancer
Enrollment 286 participants
Start Date 2022-04-07
Primary Completion 2025-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2023-12-19